Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;31(6):328-34.
doi: 10.1016/j.kjms.2015.04.002. Epub 2015 May 6.

Risks of nonadherence to hormone therapy in Asian women with breast cancer

Affiliations

Risks of nonadherence to hormone therapy in Asian women with breast cancer

Kun-Pin Hsieh et al. Kaohsiung J Med Sci. 2015 Jun.

Abstract

The aim of this study was to quantify the hormone therapy (HT) nonadherence patterns and to assess the associated risk factors in Asian women with breast cancer. This retrospective cohort study used the Taiwan Health Insurance Research Database from 2003 to 2011. Data from women with newly diagnosed primary breast cancer were identified, and persistence (without HT prescribing gap ≥ 180 days) to HT was defined through records of dispensing prescriptions. Study cohorts were further classified as adjuvant and primary HT groups. Each individual's HT utilization patterns and the medication possession ratio at overall HT course were measured. The odds ratios (ORs) of nonadherence (medication possession ratio, <80%) in adjuvant and primary HT patients were estimated using logistic regressions with adjustment of potential confounding variables. These patients had 15.6% and 23.4% nonadherence rates to HT in adjuvant and primary HT groups, respectively. In the adjuvant HT group, older age groups (≥50 years) and taking aromatase inhibitors were less likely to show nonadherence (p < 0.05). In the primary HT group, women older than 70 years were significantly less likely to exhibit nonadherence (OR = 0.53; 95% confidence interval, 0.28-0.99); however, women with presence of HT-related adverse events had significantly increased risk (OR = 1.44; 95% confidence interval, 1.02-2.03). Young age and experience of musculoskeletal and joint symptoms were identified as risk factors for nonadherence.

Keywords: Adherence; Breast cancer; Drug utilization; Hormone therapy; Nonadherence.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Haynes R.B., Sackett D.L., Taylor D.W., Roberts R.S., Johnson A.L.. Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. Clin Pharmacol Ther. 1977; 22: 125–130. - PubMed
    1. Darkow T., Henk H.J., Thomas S.K., Feng W., Baladi J.F., Goldberg G.A., et al. Treatment interruptions and non‐adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007; 25: 481–496. - PubMed
    1. Borras J.M., Sanchez‐Hernandez A., Navarro M., Martinez M., Mendez E., Ponton J.L., et al. Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ. 2001; 322: 826. - PMC - PubMed
    1. Liu G., Franssen E., Fitch M.I., Warner E.. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15: 110–115. - PubMed
    1. Fallowfield L., Atkins L., Catt S., Cox A., Coxon C., Langridge C., et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006; 17: 205–210. - PubMed

Publication types